OVERVIEW

2026 Achieve Targets in Diabetes Care (ATDC) Conference is organized by Barbara Davis Center for Diabetes (BDC) and will be held from Jul 08 - 11, 2026 at Keystone Conference Center, Dillon, Colorado, United States of America.

Description:
The ATDC Conference has been an integral part of education and case-based study of upcoming and new diabetes technology for over 30 years. This is an annual course designed to help healthcare providers caring for patients with diabetes, including but not limited to: endocrinologists/diabetes specialists, internists, pediatricians, family physicians, physician assistants, medical residents and fellows, advanced practice nurses, nurses, dietitians, social workers, and Certified Diabetes Care and Education Specialists (CDCES).

Attendees will have an opportunity to interact with leaders in the field and participate in detailed question and answer sessions with the experts. The 2026 ATDC conference will explore many facets of treating patients with both T1D and T2D. We will review the use of dual continuous glucose and ketone monitors in both T1D and T2D management especially in the inpatient setting. Continuing the theme of technology in diabetes management, there will be multiple sessions, across plenaries, on advances in hybrid closed-loop systems, and their emerging role managing T2D. Developing new algorithms as well as a look to the future with the role of Artificial Intelligence in diabetes care. The pitfalls of technology use go hand in hand with the increasing use of technology in medicine.

Attendees will have the opportunity to attend a peer-to-peer workshop where they discuss different cases and upcoming trials in the field of diabetes and obesity. We will also discuss the use of GLP1, GLP-1 + GIP analogs in the treatment, prevention, and reversal of complications of diabetes in the cardiovascular, gastrointestinal, and renal systems. We plan to discuss managing early diabetic kidney disease and “lipotoxicity”.

In addition to newer diabetes technology, there are also novel and alternate insulin delivery methods that are fast becoming a desirable option for many patients; however, the decision of when to consider these agents and the selection of appropriate patients can be challenging especially in the primary care setting. Obesity continues to be a global health epidemic and the emergence and rising incidence of obesity in T1D is becoming an increasing barrier in achieving glycemic targets. Traditional methods and novel agents to combat this epidemic will be discussed.

We will be discussing the role of dual glucose and ketone monitoring in managing diabetes during pregnancy, challenges in managing diabetes in the post-menopausal years, and different AID systems and setting lower targets during pregnancy associated with diabetes. There will be an update on the SURPASS CVOT trials, as well as a review on stem cell therapies in T1D. There will also be discussion regarding the future of cure for T1D especially using stem cells. The conference aims, using a multi-disciplinary approach, to empower providers to achieve better health beyond glycemic control in patients with diabetes. We will also host 4 keynotes across a wide range of topics over the 4-day conference.

Upon completion of the program, the participant should be able to:

  1. Compare benefits vs risks of dual continuous glucose & ketone monitoring;
  2. Identify appropriate use of GLP-1 analogs for individualized diabetes & obesity management;
  3. Evaluate different AID systems for use in T1D & T2D care;
  4. Identify common comorbidities & complications in patients with diabetes;
  5. Assess appropriate strategies for glucose management in special populations.

KEY DATES

Event Start Date
08 Jul, 2026
Event Start Date
Event End Date
11 Jul, 2026
Event End Date
Credits

Accreditation Details:
Continuing Medical Education (CME) Accreditation (MD, DO, RD, & social workers)
The University of Colorado School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Colorado School of Medicine designates this live activity for a maximum of 23.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

2025 Nursing Continuing Professional Development (NCPD) + Pharmacology (APRNs and Nurses)

Nursing Continuing Professional Development (NCPD) The University of Colorado College of Nursing is approved as a provider of nursing continuing professional development by the Colorado Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. 

This educational offering for a maximum of 25.5 contact hours (pharmacology contact hours for APRNs TBD) is provided by the University of Colorado College of Nursing Office of Continuing Education. Participants will identify at least 2 new “take home pearls” they will apply to their practice to support patients in achieving personal diabetes targets using medications, technology, and/or lifestyle changes.

  • 23.25 AMA PRA Category 1 Credits™
  • 25.5 Contact Hours
  • TARGET AUDIENCE

    PhysicianPhysician AssistantAdvanced Practice NurseEndocrinologistsStudentsFamily PhysiciansResidentsPediatriciansNursesInternistDietitianSocial WorkersAllied Health ProfessionalsFellowsTrainees

    SPECIALITIES

    Endocrinology

    SUGGESTED HOTELS

    CONFERENCE VENUE

    LocationKeystone Conference Center
    633 Tennis Club Rd

    RELATED CONFERENCES & LIVE WEBINARS

    Sep 06 - 09, 2027 | Gulf Shores, ...

    Primary Care
    20 AMA PRA Category 1 Credits™
    ...
    More actions
    US$839

    Sep 07 - 10, 2027 | Gulf Shores, ...

    Primary Care
    20 AMA PRA Category 1 Credits™
    ...
    More actions
    US$839

    May 24 - 27, 2027 | Sarasota, Florida,...

    Internal Medicine
    20 AMA PRA Category 1 Credits™
    ...
    More actions
    US$839